This educational activity will address the recent knowledge acquired in endometrial cancer mainly the indications for adjuvant RT and chemotherapy and the role of concurrent chemoradiation in high risk and locally advanced disease as well as the optimal sequencing approach when both modalities are used. In addition, the interpretation and potential impact of molecular markers will be discussed given the recent publication of the European guidelines which based their recommendations on molecular markers. Last, the interpretation and optimal management of sentinel LN biopsy and isolated tumor cells findings will be addressed.
This session will focus on providing updates in the management of cervical cancer. It will focus on the use of modern imaging and treatment techniques which are rapidly being adopted. This will include discussions of intensity modulated radiation therapy in the post-operative and definitive settings as well as how to integrate image guided adaptive brachytherapy. In addition we will review updated guidelines for target and organ at risk suggested doses for definitive cervical cancer treatment.
The activity is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, nurses and all other health professionals involved in the field of radiation oncology.
Upon completion of this activity, attendees should be able to do the following:
- Determine the indications for systemic therapy and radiation therapy in non-metastatic endometrial cancer.
- Identify the appropriate sequencing approach for adjuvant chemotherapy and radiation.
- Describe the role of molecular markers and their potential impact on adjuvant therapy.
- Interpret the significance and interpretation of sentinel LN biopsy and isolated tumor cells in LN.
- Lack of overall survival benefit in GOG 258 comparing chemoRT vs chemo alone in locally advanced disease which contradicts the findings of PORTEC 3 and complicate interpretation of data.
- Lack of randomized trials to establish the optimal sequencing approach of adjuvant chemotherapy and radiation therapy
- Paucity of studies establishing the impact of molecular markers on clinical practice and challenge in determining treatment algorithms
- Impact of ITCs on adjuvant therapy remains controversial and is mostly based on retrospective studies.
Lara Hathout, MD, FRCPC is employed by Rutgers Cancer Institute and and has no financial relationships with a commercial interest.
Mitchell Kamrava, MD is employed by Cedars Sinai Medical Center and has leadership positions with ADROP, the ABR, the American Brachytherapy Society Board of Directors and the Journal of Contemporary Brachytherapy.
All relevant relationships have been mitigated.All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.